CGS-CIMB Research

CGS-CIMB initiates Vicplas with TP of 27.5 cents, highlights medical manufacturing segment - THE EDGE SINGAPORE

Broker's Calls

CGS-CIMB initiates 'add' on Vicplas with TP of 27.5 cents, highlights medical manufacturing segment

CGS-CIMB analyst William Tng has initiated coverage on Vicplas with an “add” call and a target price of 27.5 cents.
Jiutian Chemical could nearly double its share price if 4Q21 results prove strongest in operating history - THE EDGE SINGAPORE

Broker's Calls

Jiutian Chemical could nearly double its share price if 4Q21 results prove strongest in operating history: CGS-CIMB

“We believe 4QFY2021F was the strongest quarter in Jiutian’s operating history."

Broker's Calls

CGS-CIMB lowers target price on Aztech, but remains positive on its prospects

CGS-CIMB has lowered its target price on Aztech, but still maintains that its prospects remain positive.

Broker's Calls

Broker's Digest: Genting Singapore, Nanofilm Technologies, SGX, Kimly, Digital Core REIT

See what the analysts have to say on these counters this week.

Broker's Calls

Analysts positive on Sembcorp's long-term PPA with the state of Andhra Pradesh

CGS-CIMB and Citi have kept their TPs at $2.51 and $2.52 respectively.

Broker's Calls

Analysts optimistic on AEM as it expands to take advantage of industry uptrend

With Intel announcing an expansion in Malaysia in Dec 2021, analysts are optimistic on its key test provider, AEM.

Broker's Calls

Is SPH REIT a buy or hold? See what the analysts have to say

Units in SPH REIT closed 1 cent higher or 1.04% up at 97.5 cents on Jan 12.

REITs

Keep an eye out for retail, office and hospitality S-REITs in 1QFY2022

The hospitality S-REIT subsector, in particular, were favoured by analysts from DBS and CGS-CIMB.

Broker's Calls

Analysts see strategic positives from MCT and MNACT merger

The transaction is currently subject to approval. MNACT’s delisting is slated to take place in mid-June.
×